Patrick Burnett Sells 955 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 955 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total value of $24,944.60. Following the completion of the transaction, the insider owned 119,289 shares of the company’s stock, valued at $3,115,828.68. This trade represents a 0.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, May 11th, Patrick Burnett sold 222 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $21.05, for a total value of $4,673.10.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ:ARQT opened at $26.43 on Friday. The company has a market cap of $3.31 billion, a P/E ratio of 125.86 and a beta of 1.49. The company has a quick ratio of 2.46, a current ratio of 2.68 and a debt-to-equity ratio of 0.54. Arcutis Biotherapeutics, Inc. has a 52 week low of $13.69 and a 52 week high of $31.77. The business has a fifty day simple moving average of $25.97 and a 200-day simple moving average of $24.69.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a return on equity of 15.93% and a net margin of 6.15%.The firm had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Equities research analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Needham & Company LLC upped their price target on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley increased their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Guggenheim lifted their price target on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.57.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARQT. Suvretta Capital Management LLC raised its holdings in shares of Arcutis Biotherapeutics by 14.2% in the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Arcutis Biotherapeutics by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company’s stock valued at $210,654,000 after purchasing an additional 107,846 shares in the last quarter. Polar Capital Holdings Plc grew its holdings in shares of Arcutis Biotherapeutics by 4.9% during the 4th quarter. Polar Capital Holdings Plc now owns 5,556,169 shares of the company’s stock worth $161,351,000 after purchasing an additional 257,415 shares during the period. State Street Corp grew its holdings in shares of Arcutis Biotherapeutics by 18.2% during the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after purchasing an additional 846,986 shares during the period. Finally, Morgan Stanley increased its position in Arcutis Biotherapeutics by 1.5% during the 4th quarter. Morgan Stanley now owns 4,340,239 shares of the company’s stock worth $126,041,000 after purchasing an additional 63,845 shares in the last quarter.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Needham raises price target: Needham & Company raised its price target on ARQT to $40 from $36 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. Benzinga analyst update
• Positive Sentiment: Strong Q2 results and higher guidance: Arcutis reported earnings of $0.11 per share, above estimates of $0.06-$0.09, while revenue of $129.9 million exceeded expectations of $118.9 million. Revenue increased 59% year over year and 23% sequentially, driven by demand for ZORYVE. Management raised 2026 net product sales guidance to $525 million-$540 million and reported positive operating cash flow. Arcutis second-quarter 2026 results
• Positive Sentiment: Additional ZORYVE growth opportunities: The FDA approved ZORYVE cream for plaque psoriasis in children as young as two. The FDA also accepted an application for infants with atopic dermatitis, with a decision expected by February 2027. Results from a Phase 2 vitiligo study are expected in the fourth quarter of 2026. Arcutis business update
• Neutral Sentiment: Routine insider selling: Three executives sold a combined 6,560 shares under pre-arranged Rule 10b5-1 plans to cover tax withholding tied to vested equity awards. Because the sales were administrative and represented less than 1% of each executive’s holdings, they provide limited evidence of bearish conviction. SEC insider trading filing

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.